President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication more accessible nationwide.

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, revenue from the diabetes drug Mounjaro, which has been on the market longer, has doubled, to $6.52 billion, thanks to growth outside the U.S.

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The move will start nationwide in mid-November and will have direct-to-consumer pricing through LillyDirect.

A man collapsed behind President Donald Trump during an Oval Office press conference on Thursday with drugmakers to expand coverage and reduce prices for popular obesity treatments Zepbound and Wegovy.